Updates in Immuno-Oncology from ITOC 2022

The Immunotherapy of Cancer Conference (ITOC) 2022 brought together experts in the field of immuno-oncology to hear the latest findings and discuss how to advance oncology drug development and delivery. In this podcast, we hear from Prof. Mascha Binder (Martin-Luther-Universität Halle-Wittenberg, Halle, Germany) discussing whether it is beneficial to combine immunotherapy with chemotherapy and Professor Chong Xian (Harvard Medical School, Boston, MA) on the pan synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. We also hear from Professor Sebastian Kobold (Ludwig-Maximilians-Universität München, Munich, Germany), Thaddäus Strzalkowski (Ludwig-Maximilians-Universität München, Munich, Germany) and Florian Markle (Ludwig-Maximilians-Universität München, Munich, Germany) discussing various approaches to overcoming the challenges associated with CAR-T cells in solid tumors.